ClinicalTrials.gg

Program

Topotecan

Also written as “topotecan”, “topotecan hydrochloride” and “Topotecan/Docetaxel combination”.

Its studies are mostly in Small Cell Lung Carcinoma · Ovarian Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms, led by 15 companies.

Furthest: phase 3, since Aug 14, 200233 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline180 open or runningphase 3since Aug 14, 2002Nov 2, 1999none ahead
Bristol-Myers Squibb20 open or runningphase 2since Sep 10, 2005Sep 10, 2005none ahead
AbbVie10 open or runningphase 3since Dec 10, 2015Dec 10, 2015none ahead
Advenchen Laboratories11 open or runningphase 3since Aug 28, 2015Aug 28, 2015none ahead
ascenta-therapeutics10 open or runningphase 2since Nov 7, 2006Nov 7, 2006none ahead
AstraZeneca10 open or runningphase 2since Apr 10, 2001Apr 10, 2001none ahead
BioNTech11 open or runningphase 2since Jun 3, 2024Jun 3, 2024Jun 2027phase 2 · NCT06449209
Chong Kun Dang Pharmaceutical10 open or runningphase 2since Mar 6, 2012Mar 6, 2012none ahead
Gilead Sciences11 open or runningphase 3since Jan 24, 2025Jan 24, 2025Oct 2029phase 3 · NCT06801834
Hoffmann-La Roche10 open or runningphase 3since Sep 11, 2012Sep 11, 2012none ahead
Johnson & Johnson10 open or runningphase 2since Nov 1, 1999Nov 1, 1999none ahead
Novartis10 open or runningphase 1since Jun 17, 2022Jun 17, 2022none ahead
Pfizer10 open or runningphase 2since Oct 9, 2018Oct 9, 2018none ahead
Sichuan Biokin Pharmaceutical11 open or runningphase 3since Jul 8, 2024Jul 8, 2024Dec 2026phase 3 · NCT06500026
SynerGene Therapeutics10 open or runningphase 1since Dec 18, 2014Dec 18, 2014none ahead

Also a collaborator on its studies: Eisai, baili-bio-chengdu-pharmaceutical-co-ltd and prologue-research-international.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 20 studies since Nov 1, 1999.

  1. Jun 16, 2008Phase 2 study in Small Cell Lung CarcinomaGlaxoSmithKline · NCT00698516 · 50 enrolled · United States
  2. Aug 11, 2008Phase 1 study in Solid TumoursGlaxoSmithKline · NCT00732420 · 68 enrolled · United States, Netherlands
  3. Mar 6, 2012Chong Kun Dang Pharmaceutical's first study: phase 2 study in Carcinoma, Ovarian EpithelialNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT01630018 · 141 enrolled · Korea, Republic of
  4. Sep 11, 2012Hoffmann-La Roche's first study: phase 3 study in Ovarian NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT01684878 · 208 enrolled · Austria, Belgium, Denmark and more
  5. Dec 18, 2014SynerGene Therapeutics's first study: phase 1 study in NeoplasmsNew to SynerGene TherapeuticsSynerGene Therapeutics · NCT02354547 · 18 enrolled · United States
  6. Aug 28, 2015Advenchen Laboratories's first study: phase 3 study in Endometrial NeoplasmsNew to Advenchen LaboratoriesAdvenchen Laboratories · NCT02584478 · 294 enrolled · United States, China, Italy and more
  7. Dec 10, 2015AbbVie's first study: phase 3 study in Carcinoma, Ovarian EpithelialNew to AbbVieAbbVie · NCT02631876 · 366 enrolled · United States, Belgium, Bosnia and Herzegovina and more
  8. Oct 9, 2018Pfizer's first study: phase 2 study in Sarcoma, EwingNew to PfizerPfizer · NCT03709680 · 128 enrolled · United States, Brazil, Canada and more
  9. Jun 17, 2022Novartis's first study: phase 1 study in NeuroblastomaNew to NovartisNovartis · NCT05429502 · 12 enrolled · United States, Germany, Italy and more
  10. Nov 4, 2022Phase 2 study in Ovarian NeoplasmsBristol-Myers Squibb · NCT05613088 · 106 enrolled · United States, Australia, Belgium and more
  11. Jun 3, 2024BioNTech's first study: phase 2 study in Small Cell Lung CarcinomaNew to BioNTechBioNTech · NCT06449209 · 110 enrolled · United States, Australia, South Korea and more
  12. Jul 8, 2024Sichuan Biokin Pharmaceutical's first study: phase 3 study in Small Cell Lung CarcinomaNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT06500026 · 722 enrolled · China
  13. Jan 24, 2025Gilead Sciences's first study: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)New to Gilead SciencesGilead Sciences · NCT06801834 · 695 planned · United States, Argentina, Australia and more
  14. Oct 28, 2026Phase 2 study terminatedStudy stoppedNCT05613088 · “Business objectives have changed.”

Ahead

  1. Dec 2026Primary completion: phase 3 study in Small Cell Lung CarcinomaSichuan Biokin Pharmaceutical · NCT06500026
  2. Jun 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaBioNTech · NCT06449209
  3. Oct 2029Primary completion: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)Gilead Sciences · NCT06801834

TargetBeta

TOP1 →read by rule
“DNA topoisomerase I inhibitor”ChEMBL 37, by rule

Other programs on TOP1

ProgramCompanyFurthest phaseStudies
irinotecan sucrosofateruleCSPC Pharmaceutical Groupphase 320

Studies

All 33 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more3RecruitingGilead SciencesOct 2029695
NCT06500026Small Cell Lung Carcinoma · China3Active, not recruitingSichuan Biokin PharmaceuticalDec 2026722
NCT06449209Small Cell Lung Carcinoma · United States, Australia, South Korea and more2Active, not recruitingBioNTechJun 2027110
NCT05613088Ovarian Neoplasms · United States, Australia, Belgium and more2TerminatedBristol-Myers SquibbJun 17, 2024106
NCT05429502Neuroblastoma · United States, Germany, Italy and more1TerminatedNovartisFeb 26, 202512
NCT03709680Sarcoma, Ewing · United States, Brazil, Canada and more2CompletedPfizerAug 26, 2024128
NCT02631876Carcinoma, Ovarian Epithelial · United States, Belgium, Bosnia and Herzegovina and more3CompletedAbbVieJan 2019366
NCT02584478Endometrial Neoplasms · United States, China, Italy and more3Active, not recruitingAdvenchen LaboratoriesOct 2024294
NCT02354547Neoplasms · United States1SuspendedSynerGene TherapeuticsDec 202718
NCT01684878Ovarian Neoplasms · Austria, Belgium, Denmark and more3CompletedHoffmann-La RocheJan 30, 2015208
NCT01630018Carcinoma, Ovarian Epithelial · Korea, Republic of2CompletedChong Kun Dang PharmaceuticalJun 2014141
NCT00732420Solid Tumours · United States, Netherlands1CompletedGlaxoSmithKlineJun 12, 201368
NCT00698516Small Cell Lung Carcinoma · United States2CompletedGlaxoSmithKlineMay 201050
NCT00483860Neoplasms · United States, Korea, Republic of, Netherlands1CompletedGlaxoSmithKlineFeb 6, 201259
NCT00437073Breast Neoplasms · United States, Austria, Belgium and more2TerminatedGlaxoSmithKlineJan 200922
NCT00397293Small Cell Lung Carcinoma · United States, Russian Federation, Ukraine2Completedascenta-therapeuticsDec 200836
NCT00390806Carcinoma, Non-Small-Cell Lung · United States, Canada, Hungary and more3CompletedGlaxoSmithKlineJul 2012472
NCT00361803Neoplasms · United States1CompletedGlaxoSmithKlineAug 9, 200715
NCT00320359Small Cell Lung Carcinoma · Austria, Germany3CompletedGlaxoSmithKlineFeb 2007700
NCT00276276Small Cell Lung Carcinoma · Bulgaria, Hungary, Netherlands and more3CompletedGlaxoSmithKline141
NCT00267488Endometrial Neoplasms · United States, Canada, Hungary2CompletedGlaxoSmithKlineDec 200770
NCT00259935Small Cell Lung Carcinoma · United States, Netherlands1CompletedGlaxoSmithKlineJul 5, 2007107
NCT00179712Ovarian Neoplasms · United States2CompletedBristol-Myers Squibb60
NCT00158886Carcinoma, Renal Cell · United States1TerminatedGlaxoSmithKlineAug 11, 200626
NCT00065182Carcinoma, Non-Small-Cell Lung · United States, Canada, Poland2CompletedGlaxoSmithKlineAug 30, 2007399
NCT00061308Ovarian Neoplasms · United States, Canada2CompletedGlaxoSmithKlineSep 200475
NCT00049998Carcinoma, Non-Small-Cell Lung · Australia, Austria, Belgium and more3CompletedGlaxoSmithKlineApr 2004760
NCT00046111Small Cell Lung Carcinoma · United States, Canada1CompletedGlaxoSmithKlineApr 20041
NCT00043927Small Cell Lung Carcinoma · United States, Austria, Belgium and more3CompletedGlaxoSmithKlineJan 2004760
NCT00043862Small Cell Lung Carcinoma · United States2CompletedGlaxoSmithKlineNov 200560
NCT00014690Fallopian Tube Neoplasms · United States2CompletedAstraZeneca
NCT00002395HIV Infections · United States2CompletedGlaxoSmithKline54
NCT00003827Leukemia · United States2UNKNOWNJohnson & Johnson25

How it is read

Names in the registry

  • “Topotecan”, 15 entries
  • “topotecan”, 11 entries
  • “topotecan hydrochloride”, 2 entries
  • “Topotecan/Docetaxel combination”, 1 entry
  • “Topotecan (Chemotherapy)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.